Paper Discussion Hub

Community discussion

Community discussion — not PharmaLens article intelligence.

Back to Research Passport · Compose a research post

• limitation

  Demonstration discussion: For the lecanemab record, the distinction between a statistically detectable treatment difference and a patient-meaningful change deserves careful discussion. I would also like to compare how missing outcomes and adverse-event monitoring were handled in the source report.